When was dabigatran fda approved

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations.

For more information please visit www. KG and used under license. Skip to main content. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti inflammatory drugs NSAIDs , platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the administration of PRADAXA and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment.

Promptly evaluate any signs or symptoms of blood loss e. Risk factors for bleeding include concomitant use of medications that increase the risk of bleeding e.

Reversal of Anticoagulant Effect: A specific reversal agent for dabigatran is not available. Source: Press Release. Read next. June 21, Receive an email when new articles are posted on. Please provide your email address to receive an email when new articles are posted on.

You've successfully added to your alerts. The incidence was the same across the dabigatran and enoxaparin treatment groups Dyspepsia including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort occurred more frequently in patients receiving dabigatran 4.

Gastritis-like symptoms including gastritis, GERD, esophagitis, erosive gastritis, and gastric hemorrhage were less common in patients receiving dabigatran 0. Clinical myocardial infarction was reported in 2 0. Dabigatran is marketed as Pradaxa by Boehringer Ingelheim. For more details on the drug, see the prescribing information. Venous thromboembolism can lead to complications, including swelling and discomfort near the clot, chest pain, lung damage, and even death.

The safety and efficacy of Pradaxa for treating blood clots in patients younger than 18 was evaluated in one study of pediatric patients. In this open-label study, patients were randomly assigned to receive either Pradaxa or standard of care. The study compared the two groups for the number of patients who met the composite endpoint a combination of multiple clinical endpoints , which meant that they had not died from a blood clot, their blood clots had completely resolved, and they had no additional blood clots.

Results showed that 81 The safety of Pradaxa to prevent recurrent blood clots in the same pediatric population was evaluated in an open-label, single-arm study in patients with a history of blood clots.